Leukemia Research Studies

< Back to Young Adult Cancer Research Studies Page

AML Relapse / Refractory

ADVL1521: A Phase 2 Study of the MEK Inhibitor Trametinib in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

PURPOSE: This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
 DETAILED DESCRIP ...More

Flotetuzumab and Cytarabine for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

  • Ages: < 21 years old

This phase I trial studies the side effects and best dose of flotetuzumab and how well it works with cytarabine in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Immunotherapy with flotetuzumab may induce changes in body's ...More

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

  • Ages: ≤ 30 years old

This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed ...More

M13-833: A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

PURPOSE: An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participa ...More

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

  • Ages: 1 Month to 21 Years

This phase I trial studies the side effects and how well pevonedistat, azacitidine, fludarabine phosphate, and cytarabine work in treating patients with acute myeloid leukemia that has come back or has not responded to treatment or high-risk myelodysplastic syndrome that has come back. Pevonedistat ...More

Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

  • Ages: 1 month to < 21 years old

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment. ADVL18 ...More

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)

  • Ages: 1 Year to 25 Years  

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, p ...More

Venetoclax Combined with Vyxeos for Relapsed/Refractory Acute Leukemia

  • Ages: 1 Year to 39 Years

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or no responded to treatment. This is a single-institution Phase I pilot study designed to test the safety and tolerability of c ...More

Contact Us

Contact us.

To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.